Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 17/20 | 0.49 |
| ▸ | HTR1D | P28221 | 13/20 | 0.49 |
| ▸ | HTR1B | P28222 | 12/20 | 0.49 |
| ▸ | HTR1A | P08908 | 12/20 | 0.49 |
| ▸ | CLK2 | P49760 | 2/20 | 0.43 |
| ▸ | CLK3 | P49761 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.43 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6724813 | 0.85 | HTR1A (0.55) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6722245 | 0.82 | HTR1F (0.51) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6726471 | 0.80 | HTR1A (0.52) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6670992 | 0.78 | HTR1F (0.47) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6722057 | 0.77 | HTR1F (0.47) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6724677 | 0.71 | HTR1F (0.42) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6724792 | 0.69 | HTR1A (0.49) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL10267501 | 0.69 | HTR1F (0.54) | HTR1FHTR1DHTR1BHTR1ACLK2 | |
| SCHEMBL6726991 | 0.69 | HTR1A (0.48) | HTR1FHTR1DHTR1BHTR1A | |
| Hydrochloric Acid SCHEMBL4496228 | 0.68 | HTR1F (0.53) | HTR1FHTR1DHTR1BHTR1ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | disclosed |